Reivindicaciones

CLAIMS 1<. A pharmaceutical composition for use in a method of treating erectile dysfunction in a> male human subject in need thereof, the composition comprising as an active< ingredient a human secretory leukocyte protease inhibitor or a polynucleotide coding>for the same, wherein the pharmaceutical composition is administered, in a manner which can affect the<corpora cavernosa of the penis of the male human subject in need thereof.> 2. The pharmaceutical composition for use according to claim 1, wherein the method is< for treating erectile dysfunction wherein the damage results from increased> superoxide and/or downregulation of SLPI.< 3. The pharmaceutical composition for use according to any one of claims 1 or 2, wherein>the erectile dysfunction is vascular erectile dysfunction. 4<. The pharmaceutical composition for use according to any one of claims 1 to 3, wherein>the composition is administered together, subsequently or simultaneously, with vitamin D, or a salt thereof. 5<. The pharmaceutical composition for use according to any one of claims 1 to 4, wherein>the active agent is the recombinant human secretory leukocyte protease inhibitor. 6<. The pharmaceutical composition for use according to any one of claims 1 to 4, wherein> the active ingredient is:< a. the human secretory leukocyte protease inhibitor of any of SEQ ID NO 1 to 3 or>any other sequence comprising variations in the amino acid sequences of anyone of SEQ ID NO 1 to SEQ ID NO 3, provided that the variations in the amino acid sequence maintain at least 75%, more preferably at least 80%, 90%, 95%, and most preferably 99% or more sequence identity and the molecule retains bioactivity; and/or b<. a polynucleotide sequence that may be transduced and/or transcribed in the>human or animal body leading to the expression of any one of SEQ ID NO 1 to 3 or any other sequence comprising variations in the amino acid sequences of anyone of SEQ ID NO 1 to SEQ ID NO 3, provided that the variations in the amino acid sequence maintain at least 75%, more preferably at least 80%, 90%, 95%, and most preferably 99% or more sequence identity and the molecule retains bioactivity.<7. The pharmaceutical composition for use according to any one of claims 1 to 6, wherein>the composition is administered prior to, or simultaneously to the administration of a selective phosphodiesterase 5 inhibitor (PDE5i) to the subject in need thereof.<8. The pharmaceutical composition for use according to claim 7, wherein the PDE5i is>selected from the group consisting of avanafil, lodenafil, mirodenafil, sildenafil, t<adalafil, vardenafil, udenafil, zaprinast, icariin and synthetic derivatives thereof, and>benzamidenafil.